MDxHealth
Logotype for MDxHealth SA

MDxHealth (MDXH) investor relations material

MDxHealth Q2 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for MDxHealth SA
Q2 2026 earnings summary13 Aug, 2026

Executive summary

  • Q2 2026 revenue reached $27.2 million, up 16% year-over-year and $3.3 million sequentially, marking the largest sequential increase in company history after discontinuing the Resolve UTI/mdx business and focusing on core prostate cancer diagnostics.

  • The company transitioned all Resolve customers, completed the wind-down of the Plano, Texas lab and Delta Lab, and eliminated a $10.4 million contingent liability.

  • Integration of ExoDx and sales force restructuring contributed to recovery in tissue-based diagnostics.

  • Operational discipline and focus on urology and prostate cancer diagnostics are expected to drive a return to positive adjusted EBITDA by year-end.

  • Raised $20 million in a registered direct placement in August 2026, strengthening the balance sheet.

Financial highlights

  • Q2 2026 revenue was $27.2 million, up 16% year-over-year; six-month revenue totaled $51.1 million, up 14% year-over-year.

  • Gross profit for Q2 was $17.9 million (+11% YoY); gross margin declined to 65.7% from 68.6% due to product/test mix.

  • Operating loss increased to $5.1 million (236% higher YoY); net loss rose 36% to $9.5 million, mainly due to OpEx from the ExoDx acquisition.

  • Adjusted EBITDA was negative $2.3 million for Q2, compared to positive $1.1 million in Q2 2025; six-month adjusted EBITDA was negative $7.6 million.

  • Cash and equivalents stood at $19.2 million at quarter-end; a $20 million direct placement post-quarter brings pro forma cash to $39.2 million.

Outlook and guidance

  • Full-year 2026 revenue guidance reaffirmed at $110–$115 million, representing 20–26% growth over 2025 (excluding Resolve), with expectations to return to adjusted EBITDA profitability by year-end.

  • Revenue growth is expected to be generally linear in the second half, with some Q3 seasonality.

  • Management expects accelerated tissue-based growth and sees significant opportunity for further expansion in 2027, driven by AI initiatives and new clinical data.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next MDxHealth earnings date

Logotype for MDxHealth SA
Q3 202612 Nov, 2026
MDxHealth
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next MDxHealth earnings date

Logotype for MDxHealth SA
Q3 202612 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

MDxHealth SA is a molecular diagnostics company focused on the development and commercialization of genomic tests for cancer. Specializing in urologic oncology, the company provides non-invasive tests that assist in the diagnosis and management of prostate and bladder cancers. MDxHealth’s tests use epigenetic and genetic markers to deliver accurate, personalized insights that support healthcare providers in making informed treatment decisions. The company is headquartered in Herstal, Belgium, and its shares are listed on the Euronext Brussels and the Nasdaq.